Table 1 Age and serial serum S100B levels expressed as median (interquartile range). n = number of subjects; mo, months; N/A, non-applicable.
From: Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
Control (n = 14) | Placebo (n = 20) | IFN30 (n = 15) | IFN60 (n = 15) | |
|---|---|---|---|---|
Male:Female | 6:8 n = 14 | 15:5 n = 20 | 10:5 n = 15 | 7:8 n = 15 |
Age (years) | 32 (29–44) n = 14 | 43 (36–51) n = 20 | 51 (39–53) n = 15 | 52 (43–54) n = 15 |
S100B-0mo | 0.08 (0.08–0.10) n = 14 | 0.09 (0.02–0.10) n = 20 | 0.06 (0.04–0.10) n = 12 | 0.07 (0.04–0.10) n = 14 |
S100B-3mo | N/A | 0.08 (0.05–0.10) n = 20 | 0.06 (0.05–0.10) n = 15 | 0.07 (0.04–0.10) n = 14 |
S100B-6mo | N/A | 0.10 (0.03–0.20) n = 18 | 0.07 (0.04–0.10) n = 15 | 0.07 (0.04–0.10) n = 14 |
S100B-9mo | N/A | 0.08 (0.03–0.10) n = 18 | 0.05 (0.02–0.10) n = 15 | 0.06 (0.04–0.10) n = 14 |
S100B-12mo | N/A | 0.07 (0.03–0.10) n = 17 | 0.08 (0.05–0.10) n = 15 | 0.08 (0.04–0.10) n = 14 |
S100B-15mo | N/A | 0.07 (0.02–0.10) n = 19 | 0.07 (0.04–0.10) n = 14 | 0.09 (0.04–0.10) n = 14 |
S100B-18mo | N/A | 0.07 (0.04–0.10) n = 18 | 0.06 (0.02–0.09) n = 13 | 0.09 (0.03–0.20) n = 14 |
S100B-21mo | N/A | 0.06 (0.05–0.10) n = 18 | 0.08 (0.04–0.10) n = 14 | 0.08 (0.04–0.20) n = 13 |
S100B-24mo | N/A | 0.07 (0.02–0.10) n = 18 | 0.07 (0.05–0.10) n = 15 | 0.06 (0.04–0.10) n = 13 |